Curr Opin Cardiol 2017 May 26. Epub 2017 May 26.
aCambridge Cardiac Care Centre, Cambridge bDepartment of Medicine, McMaster University, Hamilton cLMC Diabetes & Endocrinology, Brampton dLeadership Sinai Centre for Diabetes, Mount Sinai Hospital eDepartment of Internal Medicine, University of Toronto, Toronto fUniversity of Western Ontario, London, Ontario, Canada gCenter for Healthcare Delivery Sciences, Brigham and Women's Hospital, Harvard University Medical School, Boston, Massachusetts, USA hDivision of Cardiac Surgery, Keenan Research Centre for Biomedical Science, Li Ka Shing Knowledge Institute of St. Michael's Hospital iDepartments of Surgery, Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada.
Purpose Of Review
: The recent advent of a highly efficacious class of low-density lipoprotein cholesterol (LDL-C) lowering agents, the proprotein convertase subtilisin/kexin type-9 (PCSK9) inhibitors, has transformed dyslipidaemia management in patients with cardiovascular disease as well as those with familial hypercholesterolemia.Recent Findings
: Recent positive results of the landmark Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk cardiovascular outcome trial with evolocumab as an add-on to statin therapy demonstrate further reduction of cardiovascular events. Additional safety outcomes from this large randomized trial, as well as the EBBINGHAUS substudy, allay fears of neurocognitive disorder as an adverse effect of achieving very low LDL-C levels with these agents. Read More